Dr. Sunita KS Singh, MD MSc FRCPC
Claim this profileStudies Contrast-induced Nephropathy
Studies Kidney Disease
1 reported clinical trial
1 drug studied
Clinical Trials Sunita KS Singh, MD MSc FRCPC is currently running
More about Sunita KS Singh, MD MSc FRCPC
Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical TrialTreatments Sunita KS Singh, MD MSc FRCPC has experience with
- Empagliflozin
Breakdown of trials Sunita KS Singh, MD MSc FRCPC has run
Contrast-induced Nephropathy
Kidney Disease
Kidney Failure
Peritoneal Dialysis
Sodium-Glucose Cotransporter 2 Inhibitors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunita KS Singh, MD MSc FRCPC specialize in?
Sunita KS Singh, MD MSc FRCPC focuses on Contrast-induced Nephropathy and Kidney Disease. In particular, much of their work with Contrast-induced Nephropathy has involved treating patients, or patients who are undergoing treatment.
Is Sunita KS Singh, MD MSc FRCPC currently recruiting for clinical trials?
Yes, Sunita KS Singh, MD MSc FRCPC is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Sunita KS Singh, MD MSc FRCPC has studied deeply?
Yes, Sunita KS Singh, MD MSc FRCPC has studied treatments such as Empagliflozin.
What is the best way to schedule an appointment with Sunita KS Singh, MD MSc FRCPC?
Apply for one of the trials that Sunita KS Singh, MD MSc FRCPC is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.